A U.S. Food and Drug Administration medical reviewer recommended the agency not approve tafamidis, a drug developed by a Pfizer Inc. subsidiary to treat a rare genetic disorder that affects the nervous system. The reviewer said there was “inadequate” evidence the drug works, according to the Wall Street Journal.
This is the second recent setback for Pfizer. Last week, the New England Journal of Medicine published a study that found the pharmaceutical giant’s popular antibiotic azithromycin, sold under the brand name continue reading...
A study recently presented to the 2012 Thombosis and Hemostasis Summit of North America compared Pradaxa to Coumadin and found that 
An article in Canadian news magazine Maclean’s spotlights the fact that much medical and scientific research excludes female test subjects, leaving a sizable and potentially dangerous gap in clinical knowledge as to how a given medication or treatment may affect women.
In an interview with Ohio newspaper The Plain Dealer, psychologist Eric Maisel, author of “Rethinking Depression,” questions whether antidepressants are overprescribed.
